longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

YD Bio

YDES

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 739.10, above the reasonable range, cheaper than 1.15% of the time in the past 1 years, and the industry ranks 66/601, the industry Median -2.44.

739.1xP/E
$3.19Stock price
$0.00Earnings per share
739.1xP/E
Stock price$3.19Earnings per share$0.00

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-382.69x
Typical range
-610.26x–-259.26x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0185370555740

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
BMRNUSBioMarin Pharma
169.61x52.85%$12.38B
YDESUSYD Bio
739.10x--$225.99M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.